Ann: Notice of Annual General Meeting/Proxy Form , page-86

re: Ann: Notice of Annual General Meeting/Pro... MediVac, the company with the magical herpes cure wipes? - You can do better than that, BSW

I think you're missing the forest for the trees, MG - but that's ok, there will be those who also fail to see BSW's real agenda in drumming up support for other stocks.

The only fact in regards to the market is that the game never changes - charts are nothing more than a picture of human emotions... buy high... sell low... nothing's changed...

Q: Do you believe that the company needs to raise any capital based on its current cash burn rate?

Cash
30/09/2011: $4.2m
30/09/2012: $3.3m

Q: Do you believe, (as some here suggest) that OBJ intend to help fund the PNO ThermaLife product extensions in the field of analgesics, or would you be open to the idea of a 3rd party, being that of an existing partner to OBJ may already be involved, which additionally would answer the sceptics perplexities raised over non-disclosure provisions?

"The Company’s work with one of the world’s largest pharmaceutical companies also advanced with the presentation of the results of a recently fully-funded development in the area of analgesics."

Q: Do you believe that OBJ intends to fund its entire 'own products' development programs through its share holders?

"OBJ is using the partner-funded programs to prove-up products and innovations and utilize its resources to broaden its commercial base and reduce sole reliance on the time-frames of its partners."

Do you believe that one of OBJ's current partners may play a role at any stage of the "own products" development pathway?

"The treatment and/or prevention of musculoskeletal pain remains an area where OBJ believes its technology offers potential unique benefits. The ultimate aim of this program will be to develop at least one product to marketable status, such that OBJ has the choice of offering a supported finished product to an established brand partner, or launching the product directly into the market through a distribution partnership."

Q: Do you believe that if OBJ were to announce a Rights Issue under the current 15% placement capacity, it would receive the full subscribed support of its s/holders?

The total number of shares taken up via the last entitlement issue in 2009 was only 74m, or 69% 'after' both the resolution for approval of that placement was passed with 99.98% of the vote, and 'after' two significant announcements had already been made to the market, being those that were announced to the market on October 01, 2009 and November 04, 2009.

Importantly, the share price of OBJ at the time of the General Meeting notice received back in June 2009 to pass that resolution was only $0.005c.

In December 2009 the company announced a non-renounceable Rights Issue at a price of $0.023c cents per share. This represented a + 360.00% increase in sp from the date of the 2009 notice to pass that resolution. To put this in context to receipt of last Friday's notice this would be the same as OBJ doing it's next entitlement issue sometime over the next 6 months @ $0.047c per share.

Q: Is there potential for a partner to take an equity stake in OBJ?

"“P&G’s partnership with OBJ and our joint commitment of collaboration directly aligns with P&G’s business strategies,” - Jeff Weedman, P&G Vice President of Global Business Development.

Rather than offer my own opinion or speculate I'll leave you with the following directly from a contact source of someone who represents OBJ's Joint Development partner:

"At P&G, the sweet spot is for us is when we are a strategic partner with other companies. It’s not just about making a return on the investment, it’s about whether their company and technology capability can actually be used in P&G products and services to help improve those things - so we are best when we are strategically aligned. If we find a company that is of strategic interest to us, we have no hesitation and there is no limitation on how we choose to participate. It could be a question of what can P&G bring to the party that will help enable the partner company get to their next milestone? And what is P&G’s role in helping them do that? Sometimes it is investing, sometimes it’s being a BETA customer, and sometimes it’s being part of their advisory board." - Jeff Weedman, P&G Vice President of Global Business Development

"We can offer a lot more to companies through a partnership. Our money isn’t different from anybody else’s money, but we have a wealth of consumer knowledge, a great distribution system and scale that’s hard to match,” he explains. “That’s what companies that partner with us value more than anything else. With P&G as a partner, they have no trouble raising money that they need.” - P&G goes inside out

However one chooses to interpret those words, it may not confirm whether or not P&G are likely to take an equity stake in OBJ, but it does make one very clear and bold statement suggesting that OBJ, as a partner to P&G will not have any trouble raising any funds it may need.

Q: Are you able to offer even one plausible reason why the board might be interested in raising a tiny amount of capital which it doesn't even need at the current sp?

Assuming the company was to make an announcement before the date of our AGM which carried with it a significant material value to the price of our securities, only then would I accept the board may take the opportunity to issue additional securities to raise capital through its s/holders.

If Glyn's advice is correct in reply to a holder who asked if any licensing deal would be subject to our European patent allowance, then news could arrive anyday, and in my view that shouldn't come as too much of a surprise...